APLE vs FCPT

The deterministic health scores raise significant concerns, with a Piotroski F-Score of 4/9 indicating marginal financial health and no available Altman Z-Score, limiting bankruptcy risk assessment. Despite a seemingly attractive valuation with a Price/Book below 1 and a 7.7% dividend yield, the company faces declining earnings and revenue, a high payout ratio of 129.73%, and weakening profitability trends. Analysts recommend a buy, but recent earnings misses, deteriorating growth, and lack of insider buying undermine confidence. The stock trades above the Graham Number ($14.87) but well above its intrinsic value estimate of $5.11, suggesting overvaluation relative to fundamentals.

FCPT exhibits significant valuation misalignment, with a current price of $25.43 trading far above its Graham Number ($15.94) and Intrinsic Value ($8.61). While the Piotroski F-Score of 4/9 indicates stable financial health, the company's dividend profile is unsustainable with a payout ratio of 131.33%. Stagnant earnings growth (0.60% YoY) and a bearish technical trend (0/100) further undermine the bullish analyst consensus. The combination of overvaluation and poor liquidity (Current Ratio 0.48) suggests a high risk of price correction.